its not 100% sure what the influence of this is, but......
the current trial (13 patients) is 6 months from completion (12 month fu on the second group of 5 - 8 patients). The completion of the trial and release of the results will likely have some impact of the company SP and value. However, the publication of the investigation in a peer reviewed scientific journal will also have influence on the acceptance of the product by the medical community. WP reported the investigators want to publish the findings ASAP...but that wont happen until the second half of this year, and the published results could also have an impact on SP.
Lots of factors in the timeline looking forward.
Not advice, Just my 2 c ($20 post consolidation) worth.
AVR milestones, page-5
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.60 |
Change
-0.100(0.53%) |
Mkt cap ! $357.5M | |||
| Open | High | Low | Value | Volume |
| $18.70 | $18.77 | $18.21 | $664.1K | 35.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $18.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.69 | 53 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |